NZ234616A - Prevention of internal initiation of dna translation - Google Patents
Prevention of internal initiation of dna translationInfo
- Publication number
- NZ234616A NZ234616A NZ23461690A NZ23461690A NZ234616A NZ 234616 A NZ234616 A NZ 234616A NZ 23461690 A NZ23461690 A NZ 23461690A NZ 23461690 A NZ23461690 A NZ 23461690A NZ 234616 A NZ234616 A NZ 234616A
- Authority
- NZ
- New Zealand
- Prior art keywords
- codon
- internal
- sequence
- shine
- initiation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
9
2 5 4 6 i 6
Priority Da*
»
Comr'^te fpccitication Filed: / -/O-
Clsss: (5).. <?.. A ^r.CVJl J. ~j/o £j
"TZ 2 6 MAR1992
uoftcatton Drue:
a.O. Journal, No:
. NEW ZEALAND
PATENTS ACT. 1953
No.: Date:
COMPLETE SPECIFICATION
JtJtfflftorl
"PREVENTION OF PJTEimLfcffITBJTOW"
3 ' JUL199Q 4
J
SERAGEN, INC, a corporation of the State of Delaware, United States of
America, of 97 South Street, Hopkington, Massachusetts 01748, United States of America.
h'r-reby declare the invention for which XXJC we pray that a patent may be granted to riffiSS'us, and the method by which it is to be performed, to be particularly described in and by the following statement: -
(followed by page la)
- ict-
PREVENTION OF INTERNAL INITIATION Background of the Invention This invention relates to the use of recombinant DNA techniques to maximize the expression and purity of useful polypeptides.
A critical stage in the expression of a protein is the initiation of translation. Initiation is the point at which a ribosome, a mRNA molecule, a charged tRNA, and other factors are assembled in the proper relationship to allow the insertion of the initial amino acid residue of the polypeptide to be synthesized.
In prokaryotes the initiation of translation is controlled in large part by signals encoded in the sequence of mRNA molecules. Initiation of prokaryotic translation begins with the binding of a 30S ribosomal subunit to an mRNA molecule. A ribosomal binding site usually precedes the initiator codon of each independently synthesized polypeptide product. Thus a polycistronic prokaryotic message encoding three polypeptides will generally possess a ribosome binding site just 5' to each of its independently synthesized polypeptide products.
Only the core of the ribosomal binding site, the Shine-Dalgarno sequence, is conserved between various bacterial genes, and even the Shine-Dalgarno sequence is not invariant. A consensus Shine-Dalgarno sequence is AGGAGG. The Shine-Dalgarno sequence is complimentary to a pyrimidine-rich portion of the 16S ribosomal RNA component of the 30S ribosomal subunit. To function optimally in initiation, the Shine-Dalgarno sequence is generally centered approximately 4 to 20 nucleotides upstream from an initiator codon. The initiator codon in bacteria is generally AUG, but may be GUG or even UUG or AUU. The amino terminal amino acid, the first added in the synthesis of the polypeptide, is almost invariably
/v vr
07 1/
J "T 6
N-formylmethionine (fMet). Formylation occurs after the methionine has been attached to its tRNA. The formyl group blocks the amino group of the methionine. This does not prevent the use of N-formylmethionine at the 5 first position in the polypeptide chain but precludes its insertion at any other point because of the inability of the blocked amino group to participate in a peptide bond. Shortly after synthesis of the polypeptide chain begins, the formyl group is usually removed from the amino 10 terminal methionine by a deformylase. In the case of many proteins, the amino terminal methionine itself is subsequently removed by an aminopeptidase.
Binding of the 30S ribosomal subunit at the ribosomal binding site is followed by assembly of a complete 15 ribosome on the mRNA molecule. Once the ribosome has assembled at the Shine-Dalgarno sequence it scans the message until it encounters an initiator codon. Upon encountering the initiator codon the ribosome undergoes a conformational change and N-formylmethionine is inserted 20 at the first position of the amino acid chain.
After initiation the ribosome proceeds codon by codon along the mRNA inserting amino acids into the growing polypeptide chain. Termination is signaled by sequences encoded in the mRNA in the form of one of three stop 25 codons, UAA, UAG or UGA. Upon reaching an in-frame stop codon, the ribosome falls off the mRNA and addition of amino acid residues to the polypeptide chain ceases.
The codons that serve as prokaryotic initiator codons are found not only at the initial position but also at 30 other positions in the coding region. Although each of these codons directs the insertion of N-formylmethionine at the initial position, none of them normally result in the insertion of N-formylmethionine when present at other positions. When present internally, i.e., at any 35 position other than the first or initiator position, the
*
3
codons AUG, GUG, UUG, and AUU normally direct the insertion, respectively, of methionine, valine, leucine, and isoleucine.
Two classes of tRNAMet exist: tRNApMet, which carries 5 N-formylmethionine and tRNAMMet which carries methionine. When bound to the initiation site the ribosome takes part in a base pairing interaction between the 16S RNA component of the ribosome and the Shine-Dalgarno sequence. This interaction is thought to alter the 10 conformation of the ribosome in such a way that the only transfer RNA that can bind to the 30S subunit of the ribosome is tRNAFMet. When that ribosome encounters an AUG, or one of the other codons that may serve as an initiator codon, N-formylmethionine is then inserted as 15 the initial amino acid of a polypeptide. When the Shine-Dalgarno induced interaction is not present, i.e., at an internal site, tRNAfMet does not bind to the ribosome. In these instances the tRNA appropriate to the encountered codon (tRNAmMet in the case of AUG, tRNAVal in the case of 20 GUG, tRNALeu in the case of UUG, and tRNAIle in the case of AUU) binds to the ribosome with the concomitant insertion of its charged amino acid.
The invention depends on the observation that whether one 25 of the four codons AUG, GUG, UUG, AND AUU functions as an internal codon depends on the presence or absence of an appropriately placed Shine-Dalgarno sequence. The essential sequence requirements for the initiation of translation consists of an initiator codon downstream 30 from a Shine-Dalgarno sequence. Thus an internal AUG,
GUG, UUG or AUU, if coincidentally preceded by sequences that can function as a Shine-Dalgarno sequence, can result in second site or internal initiation. Second site or internal initiation results in the production of 35 a protein corresponding to the sequer"~«a the
Summary of the Invention
4
second site start codon and the first in-frame stop codon encountered.
In general, the invention features a method of preventing such undesirable initiation of translation at 5 an internal initiator codon which is preceded by an internal Shine-Dalgarno sequence, by effecting a change in the DNA of either the internal initiator codon or the internal Shine-Dalgarno sequence. The change preferably does not alter the amino acid sequence of the full length 10 translation product.
The invention provides a number of methods for eliminating internal initiation. The method employed in a particular application is dictated by the nature of the nucleotide sequence of the DNA encoding the desired full 15 length desired translation product and the amino acid sequence of the desired full length translation product.
In the most preferred embodiment, internal initiation is eliminated by effecting a change in the sequence of the internal initiator codon and in the Shine-Dalgarno 20 sequence such that the internal initiator codon is converted to a codon that does not support initiation and such that any possibility of inappropriate ribosome binding is eliminated, all without changing the amino acid sequence of the full length translation product. 25 In a less preferred embodiment, where the sequence is such that no change in the sequence of the internal initiator codon will eliminate the presence of the internal initiator codon without changing the amino acid sequence of the full length transcription product, a 30 change in the DNA sequence of the Shine-Dalgarno sequence is effected. This change is such that the functional Shine-Dalgarno sequence is destroyed without resulting in a change in the amino acid sequence of the full length translation product. r
*
In other less preferred embodiments, any change that will eliminate the existence of an internal initiator codon or destroy the superfluous functional Shine-Dalgarno sequence will result in a change in the sequence 5 of the full length translation product. In these embodiments a change in the DNA sequence is effected that will eliminate internal initiation and produce a polypeptide with the most conservative departure from the original full length translation product.
The invention improves yield of recombinant proteins and facilitates purification by preventing the production of non-functional truncated protein fragments beginning at internal initiation sites.
Other features and advantages of the invention will be
apparent from the following description of the preferred embodiments thereof, and from the claims.
toxin. The internal GTG codon, starting at nucleotide 526, is indicated.
FIG. 2 is a codon dictionary.
FIG. 3 is a table of conservative amino acid 25 substitutions.
FIG. 4 is a Shine-Dalgarno sequence in different registers with the in-frame codons of a mRNA molecule. Prevention of Internal Initiation in IL-2 Toxin
from a hybrid gene. The recombinant gene contains both a portion of the diphtheria toxin gene and the interleukin-2 (IL-2) gene. DNA encoding the diphtheria toxin's generalized eukaryotic receptor binding domain is replaced with interleukin-2 (IL-2) encoding DNA, using 35 recombinant DNA methods, as described in Murphy, —
Description of the Preferred Embodiments The drawings will first be described Drawings
FIG. 1 is the sequence of the DNA expressing IL-2-
IL-2-toxin is a 68,170 dalton fusion protein expressed
6
Patent No. 4,675,382, hereby incorporated by reference. As described in Strom et al. PTC/US89/02166, hereby incorporated by reference, IL-2-toxin can act as an IL-2-receptor-positive-cell-destroying substance.
polypeptide as a contaminant. Amino acid sequence analyses of the copurifying polypeptide indicates that the N-terminal amino acid residue of the 59,000 dalton polypeptide is threonine, and thereafter the 59,000 10 dalton polypeptide is identical to the remaining 534 amino acid residues comprising the carboxyl terminal portion of IL-2-toxin. The 59,000 dalton polypeptide is cross-reactive with anti-diphtheria toxin antibodies and anti-interleukin-2 antibodies. The antigenic 15 determinants of these antibodies are both present in the region of IL-2-toxin corresponding to the sequence of the 59,000 dalton internal start polypeptide.
The sequence of IL-2-toxin is shown in FIG. 1. The 84th codon in the mRNA specifying IL-2-toxin is GUG, 20 which encodes valine. (The 84th codon corresponds to nucleotides 526-528 in FIG. l) The 85th codon in the mRNA specifying lL-2-toxin is ACG, which encodes threonine. The 59,000 dalton polypeptide contaminant is, we believe, derived from an internal initiation of 25 translation at codon 84 in the IL-2-toxin mRNA. Internal initiation of translation occurs at the GUG codon at position 84 probably because of the presence of a highly conforming representative of the Shine-Dalgarno sequence, UGGAGG, centered 13 bases 5' of the GUG codon. GUG may 3 0 serve as an initiator codon in bacteria. Although GUG
normally specifies valine, the Shine-Dalgarno sequence 5' to the GUG codon at position 84 results in initiation-ribosome binding, ribosomal assembly, and concomitant,, insertion of N-formylmethionine. This N-formylmethionine"
The purification of IL-2-toxin yields a 59,000 dalton
7
residue, which is the first amino acid of the internal start polypeptide, is cleaved by an aminopeptidase, and thus the initial amino acid residue of the ultimately recovered internal start contaminant is threonine. This 5 threonine corresponds to the threonine at position 85 of IL-2-toxin.
Second site initiation is undesirable for a number of reasons. Second site starts may disrupt translation from properly initiated ribosomes, as well as compete with 10 initiation at the true initiation site for ribosomes,
initiation factors, charged tRNAs, and any other factors needed for production of the final protein product. Thus second site initiators may reduce the overall yield of a desired product of protein synthesis. The product of the 15 second site starts may also result in the need for additional purification steps. Products of internal initiation, when in the same reading frame, can be very similar e.g., in size, physical properties and immunological specificity, to the desired product. These 20 similarities can present particularly difficult purification problems.
Second site or internal initiation can be eliminated according to the invention by effecting an appropriate alteration in the sequence of either the codon being used 25 as the second site initiator codon or in the nearest adjacent Shine-Dalgarno sequence or in both. The most preferred alteration is one that, without altering the sequence of the desired translation product, is known unambiguously to be capable of eliminating internal 30 initiation and ribosome binding. If only a single change can be made, changes at the internal initiator codon are thus preferable to changes at the internal Shine-Dalgarno, although changes at both sites is most preferable.
Changing the third "G" in the GUG codon at position 84 ^
to "C" yields GUC, which encodes valine, but which cannot \
act as an initiator codon in the presence of a Shine-Dalgarno sequence.
This change is consistent with the fact that the final nucleotide of the codons specifying most amino acids are far less specific than are the first and second nucleotides of the codon (see FIG. 2). For example,
four codons specify valine: GUG, GUA, GUC, and GUU. Any change at the first or second nucleotide of the GUG codon would result in a change in the amino acid inserted into the polypeptide. The final nucleotide of an in-frame GUG may however be changed to any one of A, C, or U and the resultant codon will still direct the insertion of valine into the nascent polypeptide chain. The codons GUA, GUC, and GUU never, even when proceeded by a Shine-Dalgarno sequence, function as initiator codons. Thus any substitution at the third nucleotide of the GUG codon at position 84 of IL-2-toxin will eliminate internal initiation at position 84 without effecting a change in the amino acid sequence of IL-2-toxin. Standard methods for the manipulation of cloned DNA sequences, known to those skilled in the art, can be employed to effect the desired change in DNA sequence.
In other preferred embodiments, where the codon serving as the initiator codon of an internal start is UUG or AUU that is in-frame, an analogous approach is used. UUG, which normally encodes leucine, can be changed to UUA, which also encodes leucine but which cannot function as an initiator codon, even in the presence of a Shine-Dalgarno sequence. Likewise, AUU which normally encodes isoleucine can be changed to AUC, which also encodes isoleucine but never serves as an initiator codon, even in the presence of a Shine-Dalgarno sequence.
In other preferred embodiments second site initiation occurs at an in-frame AUG codon. AUG is the only codon that directs the insertion of methionine. A change at any of the three nucleotides of the AUG codon will result
in the substitution of some other amino acid for methionine in the full length polypeptide.
Second site starts at in-frame AUG codons may be eliminated in one of three ways. In a preferred 5 embodiment, the functional integrity of the Shine-
Dalgarno sequence and the internal initiator codon can be altered to eliminate internal starts. Alternatively, the internal initiator alone can be altered. The AUG serving as the second site initiator codon can be altered to a 10 codon that does not support initiation. As mentioned above, any change in an AUG codon will be expressed in the full length polypeptide. The choice of alterations should be limited to those resulting in an amino acid whose properties most resemble those of methionine. FIG. 15 3 provides a table of the most conservative amino acid substitut ions.
In other embodiments it may be preferable to eliminate internal starts by alteration of the functional internal Shine-Dalgarno sequence. Depending on the exact sequence 20 of the Shine-Dalgarno sequence and the way in which it is superimposed on the in-frame codons specifying the translation product, different options will arise. It will be possible in some instances to eliminate the functional Shine-Dalgarno sequence without altering the 25 amino acid sequence of the desired full length polypeptide. FIG. 4 depicts a Shine-Dalgarno sequence in each possible register with the in-frame codons of the corresponding polypeptides. Inspection of the dictionary of codons in FIG. 2 indicates that the Shine-Dalgarno 30 sequence in 4a can be disrupted without a change in amino acid sequence, while the changes that can be made without changing the sequence of the amino acids in the polypeptide do not unambiguously destroy the Shine-Dalgarno sequence of figure 4c. In cases where any 35 change, either in the internal initiator codon or the
Shine-Dalgarno sequence, will result in a change in the
~ " J f ' <
!. i U i ' j
made to FIG. 3 to discover the most conservative of the resulting substitutions.
In other embodiments, the internal initiator codon will be out-of-frame with the desired full length polypeptide.
For example, an in-frame sequence specifying the insertion of isoleucine and cysteine could be comprised of AUA*UGU. The final nucleotide of the isoleucine codon together with the first two nucleotides of the cysteine codon form an out-of-frame AUG. In many cases it will be 10 possible to alter the in-frame sequences in such a way that the out-of-frame initiator is destroyed without effecting a change in the amino acids inserted into the desired full length polypeptide. In the example just given, alteration to yield the in-frame sequence AUC»UGU 15 will replace the out-of-frame AUG with CUG, which never serves as an initiator codon. The new sequence will result in the insertion of the same amino acids,
isoleucine and cysteine, into the full length polypeptide.
In other preferred embodiments it will not be possible to eliminate second site starts without effecting a change in the amino acid sequence of the full length polypeptide, e.g., where the in-frame sequence AAA*UGU specifying lysine and cysteine creates an out-of-frame 25 AUG formed from the last nucleotide of the lysine codon and the first two nucleotides of the cysteine codon. The only change that can be made within the 6 nucleotides of the in-frame codons that is not expressed in the in-frame polypeptide is the change of the third nucleotide of the 30 lysine codon (here A may be changed to G without a change in the polypeptide). This change destroys the out-of-frame AUG initiator codon but creates an out-of-frame GUG initiator codon. In these and analogous situations,
second site starts may be eliminated by changes in the 35 in-frame sequence that eliminate the out-of-frame initiator codon but result in only the most conservative changes in the amino acids inserted into the desired full
A
f O-1,
length polypeptide. The results of alterations at the internal initiator codon are compared to the results of alterations at the Shine-Dalgarno sequence. Generally, the alteration that results in no or the most conservative change in amino acid sequence is chosen.
Other embodiments are within the following claims.
Claims (4)
1. A method of preventing undesired initiation of translation at an internal initiator codon in a DNA sequence encoding a polypeptide, wherein there is located upstream of said internal initiator codon a Shine-- 5 Dalgarno sequence, said method comprising altering either said internal initiator codon or said Shine-Dalgarno sequence, or both, such that inappropriate initiation of translation and/or ribosome binding is prevented.
2. The method of claim 1, wherein said internal 10 initiator codon is altered by a substitution of one or more base pairs.
3. The method of claim l, wherein said Shine-Dalgarno sequence is altered by a substitution of one or more base pairs. undesired initiation of translation at an internal initiator codon in a DNA sequence encoding a polypeptide substantially as herein described with reference to any example thereof or to the accompanying drawings.
4. A method as claimed in any one of claims 1-3 of preventing By fcHs/Thelr authorised Agent A.J. PARK & SON Per: - ■
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38424889A | 1989-07-24 | 1989-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ234616A true NZ234616A (en) | 1992-03-26 |
Family
ID=23516580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ23461690A NZ234616A (en) | 1989-07-24 | 1990-07-23 | Prevention of internal initiation of dna translation |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0484411A4 (en) |
JP (1) | JPH05501054A (en) |
AU (1) | AU6067590A (en) |
CA (1) | CA2063799A1 (en) |
NZ (1) | NZ234616A (en) |
WO (1) | WO1991001374A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003290453A1 (en) | 2002-12-20 | 2004-07-14 | Chromagenics B.V. | Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors |
BRPI0517380A (en) * | 2004-11-08 | 2008-10-07 | Chromagenics Bv | DNA molecule, expression cassette, host cell, and methods for generating a host cell expressing a polypeptide of interest and for producing a polypeptide of interest |
US8999667B2 (en) | 2004-11-08 | 2015-04-07 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
US20060195935A1 (en) | 2004-11-08 | 2006-08-31 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
ES2384391T3 (en) * | 2004-11-08 | 2012-07-04 | Chromagenics B.V. | Selection of host cells that express protein at high levels |
US8039230B2 (en) | 2004-11-08 | 2011-10-18 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
AU2007254993A1 (en) * | 2006-05-30 | 2007-12-13 | Dow Global Technologies Llc | Codon optimization method |
CN114395559A (en) * | 2014-04-25 | 2022-04-26 | 吉尼松公司 | Treatment of hyperbilirubinemia |
EP3359666A1 (en) | 2015-10-09 | 2018-08-15 | Genzyme Corporation | Early post-transfection isolation of cells (epic) for biologics production |
CA3039598A1 (en) | 2016-10-07 | 2018-04-12 | Genzyme Corporation | Early post-transfection isolation of cells (epic) for biologics production |
-
1990
- 1990-07-20 AU AU60675/90A patent/AU6067590A/en not_active Abandoned
- 1990-07-20 EP EP19900911644 patent/EP0484411A4/en not_active Withdrawn
- 1990-07-20 JP JP51108890A patent/JPH05501054A/en active Pending
- 1990-07-20 WO PCT/US1990/004113 patent/WO1991001374A1/en not_active Application Discontinuation
- 1990-07-20 CA CA 2063799 patent/CA2063799A1/en not_active Abandoned
- 1990-07-23 NZ NZ23461690A patent/NZ234616A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1991001374A1 (en) | 1991-02-07 |
AU6067590A (en) | 1991-02-22 |
EP0484411A4 (en) | 1992-06-17 |
JPH05501054A (en) | 1993-03-04 |
EP0484411A1 (en) | 1992-05-13 |
CA2063799A1 (en) | 1991-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7148579B2 (en) | Fusion partner for peptide production | |
JP2686090B2 (en) | Novel fusion protein and purification method thereof | |
KR100316004B1 (en) | Method and plasmid for production of crm protein and diphtheria toxin | |
US5122457A (en) | Expression systems utilizing bacteriophage t7 promoters, gene sequences, and t7 rna polymerase | |
JP2981286B2 (en) | Expression of tetanus toxin fragment C | |
NZ234616A (en) | Prevention of internal initiation of dna translation | |
EP2610348A1 (en) | Novel artificial translation/synthesis system | |
WO2007089093A1 (en) | Production of a soluble native form of recombinant protein by the signal sequence and secretional enhancer | |
JPH07113040B2 (en) | Fusion protein, production method thereof and use thereof | |
JPH0813273B2 (en) | Method for expressing protein and cloning vector used therefor | |
CA2385325A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
RU2114119C1 (en) | Fused protein and a method of isolation of the fused protein | |
Pohlner et al. | Sequence–specific cleave of protein fusion using a recombinant Neisseria type 2 IgA protease | |
EP0510018A1 (en) | Lipoprotein signal peptide fused to antigenic polypeptides | |
CA2294760A1 (en) | Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin | |
WO2016161983A1 (en) | Fusion carrier protein and application thereof in promoting target protein or polypeptide expression | |
EP1001980A1 (en) | Recombinant expression of insulin c-peptide | |
US7037684B2 (en) | Process for producing polypeptide having disulfide bond | |
US20110092424A1 (en) | Production of glucagon like peptide 2 and analogs | |
EP1307569B1 (en) | Preparation of a recombinant protein in a prokaryotic host cell by improved codon use | |
AU713999B2 (en) | Recombinant expression of S-layer proteins | |
US8003348B2 (en) | Method for the mass expression of an antimicrobial peptide by co-expression of a basic antimicrobial peptide and an acidic peptide using a translational coupling system | |
US20220267434A1 (en) | Long-Acting Therapeutic Fusion Proteins | |
JPH11507827A (en) | Botulinum toxin type F and uses thereof | |
US6821755B2 (en) | Preparation of a recombinant protein in a prokaryotic host cell |